AstraZeneca's strategy in CVRM is a patient-centric approach to disease treatment, so we are tackling multiple risk factors by uniting our cardiovascular (CV), metabolic and chronic kidney disease (CKD) areas into one integrated approach cardiovascular renal metabolic (CVRM). This approach means we look at the CVMD patient as a whole, rather than by disease area, because we know that cardiovascular disease is a well-known consequence of diabetes and CKD. Each of ours focus areas seek to further reduce morbidity, mortality and organ damage by addressing multiple risk factors across cardiovascular (CV) disease, diabetes and chronic kidney-disease indications. The patient-centric approach is reinforced by science-led life-cycle management programs and technologies, including early research into regenerative methods. As a Senior Pharmaceutical Sales Specialist for the Specialty Care Team, youll play a pivotal role in channeling our scientific capabilities to make a positive impact on ch...Customer Engagement, Pharmaceutical Sales, Healthcare, Cardiovascular, Senior, Sales Specialist